U.S. Phase 2A Proof-of-Concept Trial in Gastroparesis Patients
All of the company’s energies have been directed towards the completion of these trials that inform the next steps for these much-needed therapies.
Advancing these dr-ugs in their respective clinical trials allows Processa to obtain the clinical data to better define each pivotal trial as well as provide them with more insight into how the FDA will review each of these products as the company plans the road maps for designing the studies for its New Dr-ug Applications to FDA.
Read more from the company presentation here.
And as I mentioned above, PCSA has several potential catalysts to know before Wednesday's opening bell. Check them out:
No. 1 PCSA Potential Catalyst - Low Float Volatility Could Be On Display (Daily)
According to the Yahoo Finance website, PCSA has a low float.
The website reports this profile to have approximately 9.98Mn shares in its float.
Why is that important? It's important on one crucial level. Volatility.
Could positive December company news help provide a near term spark?
No. 2 PCSA Potential Catalyst - A $9.00 Analyst Target Provides Over 300% Potential Upside From Tuesday's Close
The Maxim Group has built one of the premier proprietary research platforms on Wall Street, with an emphasis on small-cap, micro-cap, and emerging growth companies.
The firm's research is both theme-based and trading-oriented with an ‘alpha-goal.’ Institutional clients, CEOs and board directors seek out their Senior Research Analysts for advice and expert opinions in their respective industry verticals.
Naz Rahman, a Vice President and Senior Research Analyst at Maxim Group covering the biotechnology sector has set a $9.00 target on Processa Pharmaceuticals, Inc. as of 12/2/22 according to a published report on the company’s website.
With this $9.00 target, there could be upside potential of over 300% for PCSA from its closing valuation Tuesday.
No. 3 PCSA Potential Catalyst - Positive Results Could Mean Big Things Ahead For This Little-Known Biotech
PCS12852 Improves Gastric Emptying in Gastroparesis Patients
- In a Phase 2A Proof-of-Concept trial, the Gastric Emptying Breath Test (GEBT) results demonstrated statistical improvement in gastric emptying in gastroparesis patients receiving 0.5 mg of PCS12852 (6 patients) as compared to placebo (8 patients) at a p < 0.10 level.
- Adverse events associated with this Phase 2A trial were mild to moderate with no clinically significant cardiovascular or serious adverse events.
- Evaluation of the effect of PCS12852 on gastroparesis symptoms is expected before the end of this year.
- Processa plans to initiate a Phase 2B trial in 2023.
HANOVER, MD, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a diversified clinical-stage company developing products to improve survival and/or the quality of life for patients who have an unmet medical need condition, announces positive gastric emptying results from its PCS12852 Phase 2A trial in patients with moderate to severe gastroparesis. This Phase 2A trial was a 4-week placebo-controlled, randomized, dose-response trial designed to evaluate the effect of PCS12852 on gastric emptying, safety, pharmacokinetics, and gastroparesis symptoms. Two dosage regimens of PCS12852 versus placebo were evaluated in patients with moderate to severe gastroparesis.
“We are pleased that this first Phase 2A study with PCS12852 was able to demonstrate a prokinetic effect and improve gastric emptying in gastroparesis patients,” said Dr. Sian Bigora, Chief Development Officer at Processa. “The data from this study will inform the design of our planned Phase 2B study. Gastroparesis continues to be a serious disease that has unmet needs, and we are hopeful that PCS12852 will ultimately help improve the quality of life of gastroparesis patients.”
Read the full article here.
No. 4 PCSA Potential Catalyst - Profile Trading Above 4 Key Lines Of Potential Support
As of after hours Tuesday (approx. 4:30PM EST), PCSA was trading above 4 potential lines of support.
Could this potential support provide some firepower towards a possible vertical shot near term?
Here's the list:
- 5-Day Simple Moving Average
- 20-Day Simple Moving Average
- 5-Day Exponential Moving Average
- 13-Day Exponential Moving Average
If support continues to grow at those levels, it could turn in the building blocks for a continued vertical move that has seen PCSA grow as much as 40% from a $1.57 low last week to this week's $2.21 high.
Watch these lines closely this week.
PCSA Recap - These Potential Catalysts Are Must-Know Material
No. 1 - Low Float Volatility Could Be On Display (Daily)
No. 2 - A $9.00 Analyst Target Provides Over 300% Potential Upside From Tuesday's Close
No. 3 - Positive Results Could Mean Big Things Ahead For This Little-Known Biotech
No. 4 - Profile Trading Above 4 Key Lines Of Potential Support
Coverage is officially initiated on PCSA. When time permits, do this: